pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,798 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1213Endpoints919BioPharma Dive354BioSpace340Fierce Biotech317onclive165raps111globenewswire health
therapy area
allOncology8257Rare Disease1941Cardiology1879Immunology1580Hematology1354Vaccines1279Pulmonology
  • Dementia care faces ambiguous loss, a unique grief that strains relationships
    Jason Karlawish, a professor of medicine and neurology at the University of Pennsylvania, wrote an opinion piece on the concept of ambiguous loss in dementia care. He reflects on a recent interview…
    STAT · 4mo agoNeutral↗ source
  • Dr. Glaucomflecken protests corporate staffing of PeaceHealth emergency department in Oregon
    Dr. Glaucomflecken, the online persona of physician Will Flanary, hosts the First Opinion Podcast where he blends humor with health‑care commentary. He has become a vocal critic of PeaceHealth’s p…
    STAT · 4mo agoNegative↗ source
← prev
page 68 of 72
next →
73
fda recalls71
fda medwatch63
fda press38
1277
Psychiatry & CNS889
Ophthalmology521
Pain503
Endocrinology & Metabolism495
Infectious Disease459
Cytokinetics’ Myqorzo hits twin efficacy targets in genetic heart disease trial, while Viridian reports positive Phase 3 data for elegrobart
Cytokinetics announced that its experimental heart‑failure drug Myqorzo achieved both primary efficacy endpoints in a study of patients with genetic cardiomyopathy, showing significant symptom impr…
STAT · 4mo agoPositive readoutPositive↗ source
  • Cytokinetics' Myqorzo hits both primary endpoints in Phase 3 trial for non-obstructive hypertrophic cardiomyopathy
    Cytokinetics announced that its drug Myqorzo achieved the dual efficacy targets in the Phase 3 ACACIA trial, which evaluated patients with non-obstructive hypertrophic cardiomyopathy (HCM), an inhe…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Hantavirus outbreak on cruise ship highlights risks of U.S. exclusion from WHO
    Three passengers have died and seven others are ill after a suspected hantavirus infection was identified on a cruise vessel anchored off Cape Verde. The World Health Organization has taken the lea…
    STAT · 4mo agoRegulatoryNegative↗ source
  • J&J's IBD combo therapy misses statistical goal but will be tested in a focused patient subgroup
    Johnson & Johnson reported that its experimental combination of Tremfya and Simponi, called JNJ-4804, did not achieve a statistically significant improvement in a Phase 2b study of inflammatory bow…
    STAT · 4mo agoNegative readoutNegative↗ source
  • Pharma's reputation among patient groups edges up to 57% but access and pricing concerns linger
    Patient groups surveyed by research firm PatientView gave drugmakers a 57% “good” or “excellent” reputation rating, the highest level since 2023. The survey covered more than 2,400 groups in 35 cou…
    STAT · 4mo agoNeutral↗ source
  • GOP Oversight Chair James Comer Targets AMA Billing Codes Over Fraud Concerns
    House Oversight Committee Chair James Comer, a Republican from Kentucky, is directing new scrutiny toward the American Medical Association's Current Procedural Terminology (CPT) billing codes, alle…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • STAT+ examines AI diagnostic claims, telehealth abortion access and Epic lawsuit in latest health tech newsletter
    STAT+ published a health‑tech newsletter that asks whether artificial intelligence has truly outperformed physicians in diagnosing disease, citing a high‑profile study on AI diagnostic performance.…
    STAT · 4mo agoNeutral↗ source
  • RFK Jr. proposes steps to curb SSRI prescriptions; J&J pushes IBD drug; French regulators fine Novo, Lilly over weight-loss ads
    U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a set of initiatives aimed at reducing the prescribing of selective serotonin reuptake inhibitors, the most widely used clas…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight
    A top Republican is asking if the AMA's codes are helping to fuel health care fraud.
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Supreme Court temporarily restores broad access to abortion pill mifepristone
    The Supreme Court issued an order on Monday that temporarily reinstates wide availability of the abortion medication mifepristone. The order follows a federal appeals court decision that had threat…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Returning doctors face unexpected hurdles and new chances to improve care in their home countries
    The opinion piece argues that the common "brain drain" story about health workers leaving low‑income nations overlooks what happens when they come back. The author cites a breast surgeon who train…
    STAT · 4mo agoNeutral↗ source
  • China's new supply chain rules threaten Western pharma as Beijing tightens control over biotech imports
    China has rapidly expanded its role in drug development, moving from less than 8% of global clinical trials in 2010 to overtaking the United States in trial volume by 2020, with more than 5,000 tri…
    STAT · 4mo agoRegulatoryNegative↗ source
  • French regulator fines Novo Nordisk and Eli Lilly for misleading weight loss ads
    French medicines regulator ANSM imposed fines on Novo Nordisk and Eli Lilly for advertising practices linked to their weight loss drugs. Novo Nordisk was fined about $2 million for ads promoting W…
    STAT · 4mo agoRegulatoryNegative↗ source
  • 5th Circuit reinstates in-person dispensing for mifepristone, prompting Supreme Court stay and industry concerns
    The 5th Circuit Court of Appeals reversed a prior ruling and required mifepristone to be dispensed only in person. Danco, the drug's maker, asked the Supreme Court for relief and received a one-wee…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Supreme Court blocks restriction, keeps mifepristone available via telehealth, mail and pharmacies
    The Supreme Court issued an order on Monday that temporarily restores broad access to the abortion medication mifepristone, overturning a recent appellate court ruling that would have limited its d…
    STAT · 4mo agoRegulatoryPositive↗ source
  • UCB to buy antibody maker targeting autoimmune diseases
    UCB announced it will acquire a company that develops antibody treatments for autoimmune disorders. The deal expands UCB’s pipeline in a therapeutic area where it seeks to strengthen its market pos…
    STAT · 4mo agoDealNeutral↗ source
  • Two drugmakers petition Supreme Court to reinstate mail-order access to abortion pill mifepristone
    Two drugmakers, Danco Laboratories and GenBioPro, have asked the U.S. Supreme Court to restore mail-order distribution of mifepristone, the abortion pill. The request follows a recent appellate co…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Federal appeals court rules mifepristone can only be dispensed in person, blocking mail distribution
    A federal appeals court issued a ruling that mifepristone, the medication used for medical abortions, must be provided only in person at clinics. The decision overturns the FDA regulation that had…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Latus Bio secures $42 million to launch Huntington’s disease gene therapy trial
    Biotech startup Latus Bio announced it has raised $42 million to fund its first clinical trials, including a gene‑therapy program aimed at Huntington’s disease. The capital will be used to seek FDA…
    STAT · 4mo agoDealPositive↗ source
  • New visa hurdles push foreign PhD scientists to abandon US labs for home-country jobs
    Recent data show a decline in applications from international students and researchers to U.S. labs, as new immigration procedures create uncertainty. The article follows a PhD candidate from Indi…
    STAT · 4mo agoNegative↗ source
  • New study shows AI tools in emergency rooms are being overhyped, experts caution
    A recent analysis of artificial‑intelligence applications in emergency departments concluded that the technology’s impact is far more modest than many headlines suggest. The authors warned that exp…
    STAT · 4mo agoNegative↗ source
  • Study finds fatherhood may lower early mortality, calls for more focus on paternal deaths
    Researchers published a letter in JAMA Pediatrics calling for greater study of paternal deaths, noting that being a father may lower early mortality. The authors cite a pilot study from Georgia th…
    STAT · 4mo agoNeutral↗ source
  • Rodent-borne hantavirus suspected in cruise ship outbreak that killed three and sickened others
    A rodent-borne illness is believed to be behind a recent cruise ship outbreak that has resulted in three deaths and several illnesses, according to health officials. The disease, known as hantavir…
    STAT · 4mo agoNeutral↗ source